Format

Send to

Choose Destination
J Cell Biochem. 2012 Mar;113(3):725-34. doi: 10.1002/jcb.23402.

Immunotherapy for metastatic melanoma.

Author information

1
Yale Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, Connecticut 06451, USA.

Abstract

Melanoma has traditionally been considered an immunogenic tumor. A number of approaches have been studied for enhancement of antitumor immunity. The first cytokine approved for the treatment of metastatic melanoma, interleukin-2, has resulted in prolonged responses in a small subset of patients, providing hope that immunotherapy might be useful for this disease. Ipilimumab, a monoclonal antibody to CTLA-4, was recently approved and a number of other promising investigational approaches are currently being pursued. This manuscript discusses more recent advances in the treatment of melanoma employing a variety of immune-enhancing approaches.

PMID:
22006439
DOI:
10.1002/jcb.23402
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center